Two chemotherapy drugs for bladder cancer after BCG
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older.
- You have high-risk non-muscle-invasive bladder cancer that did not fully respond to BCG treatment.
- You have recently (within 8 weeks) had a bladder exam or surgery to confirm the cancer.
- You are not able to have or have decided not to have bladder removal surgery.
- You are not pregnant or breastfeeding and will avoid pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests whether putting two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can treat low-grade bladder cancer that is at intermediate risk. The goal is to see if this approach can help people avoid more invasive treatments.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.